Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
López, Tessy; Islas, Emma Ortíz; Alvarez Lemus, Mayra A.; González, Richard Donald (2011)
Publisher: CoAction Publishing
Journal: Nano Reviews
Languages: English
Types: Article
Subjects: sol-gel silica, local delivery, GBM, TP1-1185, Pt(NH3)4Cl2/SiO2, nanotechnology, nanomedicine, Chemical technology, Short Communication
In vivo suppression of glioblastoma multiforme (GBM) in Wistar rats using silica-shelled biocatalytic Pt(NH3)4Cl2 nanoparticles is reported. These nanoparticles were synthesized by a sol-gel technique and characterized by SEM and HRTEM imaging. We confirmed morphological uniformity (30 nm) and surface acidity of the nanoparticles, respectively, by TEM imaging and FTIR spectral analysis. Interestingly, treatment of Wistar rats intraperitoneally inoculated with C6 cells using the biocatalysts resulted in considerable tumor shrinkage. Efficiency of the biocatalyst to shrink a tumor is superior to that by the commercial cytotoxic agent cisplatin. The tumor suppression property of Pt(NH3)4Cl2 nanoparticles is attributed to catalytic damage of DNA in C6 cells. Keywords: nanotechnology; nanomedicine; local delivery; GBM; Pt(NH3)4Cl2/SiO2; sol-gel silica (Published: 13 January 2011) Citation: Nano Reviews 2011, 2: 5461 - DOI: 10.3402/nano.v2i0.5461 Access the supplementary material to this article: Sample preparation, Characterization, Animal model, Histological techniques (see Supplementary files in the column to the right - under Reading Tools).
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Chisholm B, Singer G. A new type of cannula for central administration of drugs in rats. Physiol Behav 1970; 5: 1069 70.
    • 2. Covian MR, Gentil CG, Antunes-Rodrigues J. Water and sodium chloride intake following microinjections of angiotensin II into the septal area of the rat brain. Physiol Behav 1972; 9: 373 6.
    • 3. Broekkamp CL, Van Den Bogaard JH, Heijnen HJ, Rops RH, Cools AR, Rossum MV. Separation of inhibiting and stimulating effects of morphine on self-stimulation behavior by intracerebral microinjections. Eur J Pharmacol 1976; 36: 443 6.
    • 4. Ervin GN, Fink JS, Young RC, Smith GP. Different behavioral responses to L-DOPA after anterolateral or posterolateral hypothalamic injections of 6-hydroxydopamine. Brain Res 1977; 132: 507 20.
    • 5. Gutman RL, Peacock G, Lu DR. Targeted drug delivery for brain cancer treatment. J Control Rel 2000; 65: 31 41.
    • 6. Janes KA, Fresnau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Rel 2001; 73: 255 67.
    • 7. Allison RR, Mota HC, Bagnato VS, Sibata CH. Bionanotechnology and photodynamic therapy state of the art review. Photodiag Photodynam Ther 2008; 5: 19 28.
    • 8. Grossman SA, Reinhard C, Colvin OM, Chasin M, Brundrett R, Tamargo RJ, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992; 76: 640 7.
    • 9. Wang PP, Frazier J, Brem H. Local drug delivery to the brain. Adv Drug Deliv Rev 2002; 54: 987 1013.
    • 10. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Cochrane Database of Systematic Reviews (Online) [Cochrane Database Syst Rev], ISSN: 1469-493X, 2008.
    • 11. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 2006; 32: 74 89.
    • 12. Van Nifterik KA, Van den Berg J, Stalpers LJA, Lafleur MVM, Leenstra S, Slotman BJ, et al. Differential radiosensitizing potential of temozolomide in mgmt promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 2007; 69: 1246 53.
    • 13. CBTRUS. Statistical report: primary brain tumors in the United States, 1998 2002 (Central Brain Tumor Registry of the United States, 2008).
    • 14. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. for the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy and The National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987 96.
    • 15. Plowman PN, Kingston JE, Sebag-Montefiore D, Doughty D. Clinical efficacy of perceived 'CNS friendly' chemoradiotherapy for primary intracranial germ cell tumours. Clin Oncol 1997; 9: 48 53.
    • 16. Bauman GS, Sneed PK, Wara WM, Stalpers LJA, Chang SM, Mcdermott MW, et al. Reirradiation of CNS primary tumors. Int J Radiat Oncol Biol Phys 1996; 36: 433 41.
    • 17. Gonzalez-Vadillo AM, Alvarez-Valdes A, Moneo V, Blanco F, Diaz RG, Carnero A, et al. Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death. J Inorg Biochem 2007; 101: 551 8.
    • 18. Ranconi L, Sadler PJ. Using coordination chemistry to design new medicines. Coord Chem Rev 2007; 251: 1633 48.
    • 19. Arrieta O, Guevara P, Escobar E, Garc´ıa-Navarrete R, Pineda B, Sotelo J. Blockage of angiotesin II type I receptor decreases the snthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Brit J Cancer 2005; 92: 1247 52.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article